CBL10–AKT1 Kinase-Independent Inhibition: A Hypothesis-Level Curation Review

Target gene: CBL10 (Calcineurin B-Like protein 10), Arabidopsis thaliana (ARATH, NCBITaxon:3702)
UniProt: Q7FRS8
Hypothesis slug: cbl10-akt1-inhibition
GO term under test: GO:0019870 — potassium channel inhibitor activity (MF)
Seed reference: PMID: 23331977 (Ren et al. 2013)

Executive Judgment

Verdict: Partially supported, single-source, non-core — adding GO:0019870 would be over-annotation.

The seed hypothesis has two parts, and they diverge sharply in strength. The first part — that CBL10 directly inhibits the inward-rectifying K⁺ channel AKT1 by physical binding, independently of CIPK kinase activity — is accurately reported by Ren et al. 2013 and is internally well-supported within that single paper. The authors assembled a genuinely multi-method evidence package: physical interaction by yeast two-hybrid (Y2H), bimolecular fluorescence complementation (BiFC), and co-immunoprecipitation (co-IP); functional impairment of AKT1-mediated inward K⁺ currents in two independent electrophysiological systems (Xenopus oocytes and Arabidopsis root-cell protoplasts); CBL10-overexpression lines phenocopying akt1 loss-of-function (low-K⁺ sensitivity, reduced K⁺ content); and a Y2H competition assay suggesting CBL10 competes with CIPK23 for AKT1 binding.

The second part of the hypothesis — that this inhibition "has been independently replicated or corroborated in planta … and is not contradicted by later work" — fails. A systematic replication audit (NCBI ELink citedin on all 76 PubMed articles citing PMID:23331977 through 2026, plus a 105-record Europe PMC full-text co-mention search for "CBL10" AND "AKT1") found zero independent primary studies that re-measured CBL10 effects on AKT1 currents or on root K⁺ in cbl10 loss-of-function lines. The in-planta support that does exist is overexpression-based, not derived from cbl10-null plants, so it cannot distinguish a physiological inhibitory role from an overexpression artifact. Later works citing the CBL10–AKT1 link are reviews, not replications.

Critically for curation: GO:0019870 is not currently annotated to CBL10. QuickGO retrieval for Q7FRS8 shows that the two annotations derived from Ren 2013 are the conservative BP term GO:0043266 (regulation of potassium ion transport, IMP) and GO:0005515 (protein binding, IPI) — not the specific inhibitor MF term. The evidence does not justify promoting the regulatory claim to a dedicated molecular-function inhibitor term, for three reasons: (1) it rests on a single laboratory with no independent replication; (2) the in-planta data are overexpression-only; and (3) CBL10's behavior toward K⁺ transport systems is not uniformly inhibitory — it activates the high-affinity K⁺ transporter HAK5 in a kinase-dependent manner (Ragel et al. 2015), the opposite sign and opposite mechanism from the AKT1 story. The recommended action is to retain the conservative GO:0043266 annotation as non-core and reject the proposed GO:0019870 term.

Key Findings

Finding 1 — Ren 2013 is the sole primary source; no independent in-planta replication exists post-2013

Ren et al. 2013 (PMID: 23331977) remains the only primary report of CBL10's direct, kinase-independent inhibition of AKT1. The paper itself is methodologically thorough. It reports, in the authors' own words, that "CBL10 directly interacted with AKT1, as verified in yeast two-hybrid, BiFC and co-immunoprecipitation experiments," and that "the results of electrophysiological analysis in both Xenopus oocytes and Arabidopsis root cell protoplasts demonstrated that CBL10 impairs AKT1-mediated inward K⁺ currents." The mechanistic claim is explicit: "the present study revealed a CBL-interacting protein kinase-independent regulatory mechanism of calcineurin B-like proteins in which CBL10 directly regulates AKT1 activity and affects ion homeostasis in plant cells."

The replication audit was deliberately exhaustive. Using NCBI ELink citedin, all 76 PubMed articles citing PMID:23331977 through 2026 were enumerated and screened; a complementary Europe PMC full-text search for co-mentions of "CBL10" and "AKT1" returned 105 records. None of these constitutes an independent primary re-measurement of CBL10 effects on AKT1 inward currents or on root K⁺ content in cbl10 loss-of-function lines. The AKT1-focused follow-up literature instead converges on different regulators: AtKC1 and CIPK23 (PMID:26829980) and the structural basis of CIPK23 recognition of AKT1 (PMID:32015077) — neither of which involves CBL10. Works that do cite the CBL10–AKT1 link (e.g., PMID:33519853, PMID:27618104, PMID:32117382) are review articles that propagate the original claim rather than test it.

This matters for curation because single-source, unreplicated functional claims — even internally strong ones — warrant conservative annotation. The claim is credible but not corroborated.

Finding 2 — CBL10's effect on K⁺ transport is context-dependent, not uniformly inhibitory

The hypothesis treats CBL10 as a K⁺ channel inhibitor, but CBL10's documented relationship with K⁺ transport systems is bidirectional. Ragel et al. 2015 (PMID: 26474642) showed that "the Ca²⁺ sensors calcineurin B-like (CBL1), CBL8, CBL9, and CBL10, together with CBL-interacting protein kinase23 (CIPK23), activated HAK5 in vivo," increasing both the K⁺ affinity and Vmax of the high-affinity K⁺ transporter HAK5 via CIPK23-mediated phosphorylation of the HAK5 N-terminus.

This is the opposite sign and opposite mechanism from the AKT1 story:

A single gene product that both activates one K⁺ uptake system (kinase-dependently) and inhibits another (kinase-independently) cannot cleanly carry a uniform molecular-function term of "potassium channel inhibitor activity." The 2020/2021 CBL10 review (PMID:33519853) itself frames CBL10 as versatile — able to "activate (in a CIPK-dependent manner) or repress (by direct interaction) downstream targets" at different subcellular locations. This context-dependence argues against a specific inhibitor MF term and in favor of the more neutral regulatory BP term.

Finding 3 — GO:0019870 is NOT currently annotated; the existing Ren-2013 annotations are conservative

A QuickGO annotation retrieval for Q7FRS8 returned 23 annotations. The two that trace to PMID:23331977 are:

• GO:0043266 — regulation of potassium ion transport (BP; IMP / ECO:0000315; TAIR)
• GO:0005515 — protein binding (MF; IPI / ECO:0000353; TAIR)

The molecular-function term under test, GO:0019870 (potassium channel inhibitor activity), is absent from the current annotation set. The protein-binding annotation is supported directly by the Ren 2013 interaction data: "CBL10 directly interacted with AKT1, as verified in yeast two-hybrid, BiFC and co-immunoprecipitation experiments."

CBL10's remaining annotations center on its core, independently replicated biology: calcium ion binding (GO:0005509, IDA PMID:17449811), kinase binding (GO:0019900), hyperosmotic salinity response (GO:0042538, IMP PMID:17825054), monoatomic ion homeostasis (GO:0050801), detection of calcium ion (GO:0005513), calcium-mediated signaling (GO:0019722); and localization to the plant-type vacuole membrane (GO:0009705, IDA PMID:17825054), plasma membrane (GO:0005886, IDA PMID:17449811), vacuolar membrane, cytoplasm, and endosome. This is the profile of a Ca²⁺ sensor whose primary characterized role is Na⁺ compartmentation and salt tolerance — not a dedicated channel inhibitor.

Finding 4 — Final verdict: partially supported, over-annotation if promoted to GO:0019870

Consolidating the three-part audit:

1. Internal strength (positive): Ren 2013 provides multi-method evidence — Y2H + BiFC + co-IP interaction; AKT1 inward-current impairment in oocytes and root protoplasts; CBL10-OE phenocopying akt1; and a CIPK23 competition assay. The mechanism proposed is competitive displacement: "the results from the yeast two-hybrid competition assay indicated that CBL10 may compete with CIPK23 for binding to AKT1 and negatively modulate AKT1 activity." Note the hedged "may" from the single source.
2. Replication (negative): 76/76 citing papers and 105 Europe PMC records screened → 0 independent primary replications of AKT1-current inhibition; in-planta support is overexpression-only, not cbl10-null.
3. Conflicts (negative/qualifying): CBL10 activates HAK5 kinase-dependently (PMID:26474642); the mainstream AKT1 negative regulator is AtKC1 (PMID:26829980); CBL10 is absent from the CIPK23 structural activation model (PMID:32015077); and CBL10's core replicated function is Ca²⁺-sensor-mediated Na⁺/salt tolerance (PMID:31100786, PMID:17825054).

The mechanism described — competitive displacement of an activating kinase (CIPK23) from the channel — is more naturally captured by a regulation term than by an intrinsic inhibitor activity term, because the "inhibition" is competitive and context-dependent rather than a stoichiometric channel-blocking activity.

Evidence Matrix

Mechanistic Model / Interpretation

The immediate molecular function under test is whether CBL10 intrinsically inhibits the AKT1 channel by direct physical binding, independent of CIPK kinase activity. The Ren 2013 model is best represented as competitive regulation rather than channel blockade:

   ACTIVATING PATHWAY (canonical)          PROPOSED CBL10 PATHWAY (Ren 2013)
   ------------------------------          --------------------------------
   CBL1/9  →  CIPK23  →  (phospho)         CBL10  —|  AKT1   (direct binding,
      |                      |                        |       no kinase step)
      └──→ binds AKT1 ───────┘                        └─ competes with CIPK23
           ↑ AKT1 inward K+ current ↑           ↓ AKT1 inward K+ current ↓

Direct gene-product activity (what the MF term would assert): physical binding to AKT1 and reduction of AKT1 inward K⁺ current. This is supported in vitro/oocyte and in root protoplasts within one study.

Downstream / inferred effects (NOT the MF term): altered root K⁺ uptake, K⁺/Na⁺ content, and low-K⁺ sensitivity. In Ren 2013 these in-planta readouts come from overexpression lines, so they report the consequence of excess CBL10, not the physiological requirement for CBL10 — a cbl10-null phenotype on AKT1 currents or root K⁺ was not demonstrated. CBL10's primary, independently replicated function is as a Ca²⁺ sensor controlling Na⁺ compartmentation and salt tolerance via CIPK24/SOS2 at the tonoplast and plasma membrane. The AKT1-inhibition activity, even if real, is a secondary/context-specific branch of CBL10 biology.

The competing interpretation is important: because the mechanism is competitive displacement of an activating kinase (CIPK23) rather than a stoichiometric pore block, the correct ontology representation is a regulation relationship (GO:0043266), not an intrinsic inhibitor molecular activity (GO:0019870). Molecular-function "inhibitor activity" terms imply a direct, defined inhibitory biochemical action; a competitive binder that merely excludes a positive regulator does not satisfy that definition cleanly.

Evidence Base

• Calcineurin B-like protein CBL10 directly interacts with AKT1 and modulates K⁺ homeostasis in Arabidopsis — PMID: 23331977. The seed and sole primary source. Provides the complete evidence package (interaction, two-system electrophysiology, OE phenotype, CIPK23 competition). Supports the molecular claim but is single-lab and uses OE for in-planta readouts.
• The CBL-Interacting Protein Kinase CIPK23 Regulates HAK5-Mediated High-Affinity K⁺ Uptake in Arabidopsis Roots — PMID: 26474642. Shows CBL10 activates HAK5 kinase-dependently. Qualifies/competes with a uniform inhibitor assignment by demonstrating opposite-sign, opposite-mechanism behavior on a different K⁺ system.
• Calcineurin B-Like Proteins CBL4 and CBL10 Mediate Two Independent Salt Tolerance Pathways — PMID: 31100786. Reinforces CBL10's core Ca²⁺-sensor/Na⁺-salt-tolerance role, contextualizing AKT1 inhibition as non-core.
• Calcium-Regulated Phosphorylation Systems Controlling Uptake and Balance of Plant Nutrients — PMID: 32117382. Review-level orientation on CBL-CIPK nutrient control; propagates (does not replicate) the CBL10–AKT1 link.
• AtKC1/CIPK23 (PMID:26829980) and CIPK23–AKT1 structure (PMID:32015077): the mainstream AKT1 regulatory literature, in which AtKC1 is the characterized negative regulator and CBL10 does not appear — competing context the curator should weigh.
• CBL10 review (PMID:33519853): review-level synthesis describing CBL10 as a versatile activator-or-repressor.

GO Curation Implications

Lead (requires curator verification): Do not add GO:0019870 (potassium channel inhibitor activity) to CBL10/Q7FRS8. Retain the existing conservative annotations derived from Ren 2013 and treat them as non-core.

• Molecular Function: The specific MF term GO:0019870 is not justified. The underlying activity is a competitive, context-dependent modulation (displacement of CIPK23) rather than an intrinsic channel-blocking activity, and CBL10 shows the opposite (activating) effect on HAK5. The existing MF annotation GO:0005515 (protein binding, IPI) is defensible from the interaction data, though it should be viewed as minimally informative; a more specific MF is not supported by replicated evidence. If any MF were considered, "calcium ion binding" (GO:0005509, IDA) and "kinase binding" (GO:0019900) better reflect CBL10's core, replicated molecular activities.
• Biological Process: Retain GO:0043266 (regulation of potassium ion transport, IMP) as the appropriate, conservative representation of the Ren 2013 result. It captures the regulatory relationship without overcommitting to a mechanism (inhibition) that is single-source and context-dependent.
• Cellular Component: No change prompted by this hypothesis; CBL10's CC annotations (plasma membrane, vacuolar/tonoplast membrane) are independently supported (IDA, PMID:17449811, PMID:17825054).

Net action: Reject the proposed GO:0019870; keep GO:0043266 + GO:0005515 as non-core, single-source annotations pending independent replication.

Conflicts and Alternatives

1. Opposite-sign activity on HAK5 (PMID:26474642): CBL10 positively and kinase-dependently activates HAK5, directly conflicting with a blanket "K⁺ channel inhibitor" characterization and implying that CBL10's effect depends on the target and the CIPK partner.
2. Alternative AKT1 negative regulator (AtKC1): The replicated, mainstream negative regulator of AKT1 is AtKC1 (PMID:26829980), and the canonical AKT1-activation model is built on CIPK23 (PMID:32015077) — CBL10 is absent from both. The curation risk is attributing a specific inhibitor MF to CBL10 when the field's consensus AKT1 inhibitor is a different protein.
3. Overexpression artifact risk: The in-planta readouts in Ren 2013 are overexpression-based. Overexpressed CBL10 may titrate shared CIPK partners or mislocalize, producing phenotypes that do not reflect endogenous function — a classic source of over-interpretation.
4. Mechanism mismatch: The proposed mechanism is competitive displacement of CIPK23 ("may compete"), which is a regulatory interaction, not a stoichiometric pore block. GO:0019870 implies an intrinsic inhibitory molecular activity that the competition model does not cleanly satisfy.
5. No paralog confusion detected, but adjacent: CBL10 is one of ten Arabidopsis CBLs; the HAK5 study shows CBL1/8/9/10 act partly redundantly. Curators should ensure AKT1-inhibition annotations are not generalized across the CBL family from a CBL10-specific (and unreplicated) observation.

Limitations and Knowledge Gaps

• No independent replication (checked: 76 citing papers + 105 Europe PMC records; found: 0). Why it matters: single-source functional claims are fragile; GO best practice favors conservative terms until corroborated. Resolution: an independent lab re-measuring AKT1 currents with/without CBL10.
• No cbl10 loss-of-function electrophysiology (checked: Ren 2013 used OE for in-planta readouts). Why it matters: OE phenotypes cannot establish a physiological requirement for CBL10 in restraining AKT1. Resolution: AKT1 inward-current and root K⁺-uptake measurements in a cbl10-null background.
• Mechanistic ambiguity of "inhibition" (checked: competition assay hedged as "may"). Why it matters: distinguishes an intrinsic MF (GO:0019870) from a competitive regulatory interaction (better served by GO:0043266). Resolution: reconstitution with defined CBL10:CIPK23:AKT1 stoichiometry and direct biophysical binding/competition constants.
• Localization/compartment match (checked: CBL10 annotated at tonoplast + PM; AKT1 is PM). Why it matters: an inhibitory interaction requires co-localization at the plasma membrane; CBL10's dominant characterized role is tonoplast/Na⁺. Resolution: quantitative co-localization and in vivo interaction at the PM under physiological conditions.
• No structural data for a CBL10–AKT1 complex (checked: structural literature covers CIPK23–AKT1 only). Why it matters: structure would clarify whether CBL10 occludes the CIPK23 site or acts allosterically. Resolution: cryo-EM/crystallography or AlphaFold-Multimer modeling of CBL10–AKT1.

Discriminating Tests

1. Independent cbl10-null electrophysiology: Measure AKT1-mediated inward K⁺ currents in root protoplasts from cbl10 loss-of-function vs. wild type (and vs. akt1). A physiological inhibitory role predicts increased AKT1 current in cbl10-null plants. This is the single most decisive missing experiment.
2. Root K⁺ uptake/content in cbl10-null under low K⁺: Directly test whether endogenous CBL10 restrains K⁺ uptake, complementing OE data.
3. Kinase-independence confirmation: Reconstitute AKT1 in oocytes with a non-catalytic CIPK (or no CIPK) ± CBL10, and with a CBL10 variant unable to bind CIPKs, to confirm inhibition is CIPK-independent in a second lab.
4. Competition quantification: Measure binding/competition constants for CBL10 vs. CIPK23 on AKT1 (SPR/ITC/BLI) to decide whether "inhibition" is competitive displacement (→ GO:0043266) or an intrinsic block (→ GO:0019870).
5. AlphaFold-Multimer CBL10–AKT1 vs. CIPK23–AKT1 modeling: A public, programmatic comparison to test whether CBL10 plausibly occupies the CIPK23-binding surface of AKT1.

Proposed Follow-up Experiments / Actions (Curation Leads)

All items below are leads requiring curator verification.

• Action: Reject the proposed addition of GO:0019870 (potassium channel inhibitor activity) to CBL10/Q7FRS8. Retain GO:0043266 (regulation of potassium ion transport, IMP, from PMID:23331977) and GO:0005515 (protein binding, IPI) as non-core, single-source annotations.
• Candidate reference + snippet to verify (supports regulatory, not inhibitor-MF, interpretation): PMID:23331977 — "the results from the yeast two-hybrid competition assay indicated that CBL10 may compete with CIPK23 for binding to AKT1 and negatively modulate AKT1 activity." Verify that "may compete" and "modulate" are preserved to avoid over-strong wording.
• Candidate conflicting reference + snippet: PMID:26474642 — "the Ca²⁺ sensors calcineurin B-like (CBL1), CBL8, CBL9, and CBL10, together with CBL-interacting protein kinase23 (CIPK23), activated HAK5 in vivo." Verify and flag as evidence against a uniform inhibitor MF term.
• Candidate GO term (if any MF change is desired): Prefer no new specific MF; if a BP qualifier is wanted, GO:0043266 already covers the relationship. Do not promote to GO:0019870.
• Suggested curator questions: (1) Has any post-2013 study measured AKT1 currents or root K⁺ in a cbl10-null? (2) Is the "inhibition" competitive (CIPK23 displacement) or intrinsic? (3) Should CBL10's bidirectional K⁺-transport behavior preclude a specific inhibitor MF?
• Suggested experiments (for the review's "needs evidence" field): cbl10-null AKT1 electrophysiology; cbl10-null root K⁺ uptake; independent-lab oocyte reconstitution; CBL10–AKT1 binding/competition thermodynamics.

Summary Table — Hypothesis Scorecard

Report generated from a 3-iteration autonomous curation review. Primary evidence from Ren et al. 2013 (PMID:23331977); replication audit via NCBI ELink citedin (76 papers) and Europe PMC full-text search (105 records); GO state via QuickGO (Q7FRS8); conflicting evidence from Ragel et al. 2015 (PMID:26474642).

Artifacts

• OpenScientist final report
• OpenScientist final report